US 12,275,704 B2
Heterocyclic compounds and their uses
Mingda Bi, Simi Valley, CA (US); and Robert Kuehl, San Francisco, CA (US)
Assigned to CYTOKINETICS, INC., South San Francisco, CA (US)
Filed by Cytokinetics, Inc., South San Francisco, CA (US)
Filed on Dec. 6, 2023, as Appl. No. 18/531,424.
Application 15/926,411 is a division of application No. 14/210,713, filed on Mar. 14, 2014, granted, now 9,951,015, issued on Apr. 24, 2018.
Application 18/531,424 is a continuation of application No. 17/806,033, filed on Jun. 8, 2022, granted, now 11,884,630.
Application 17/806,033 is a continuation of application No. 16/579,360, filed on Sep. 23, 2019, granted, now 11,384,053, issued on Jul. 12, 2022.
Application 16/579,360 is a continuation of application No. 15/926,411, filed on Mar. 20, 2018, granted, now 10,421,726, issued on Sep. 24, 2019.
Claims priority of provisional application 61/785,763, filed on Mar. 14, 2013.
Prior Publication US 2024/0217933 A1, Jul. 4, 2024
This patent is subject to a terminal disclaimer.
Int. Cl. C07D 213/75 (2006.01); A61K 9/20 (2006.01); A61K 31/496 (2006.01); A61K 47/38 (2006.01)
CPC C07D 213/75 (2013.01) [A61K 9/2013 (2013.01); A61K 9/2018 (2013.01); A61K 9/2054 (2013.01); A61K 31/496 (2013.01); A61K 47/38 (2013.01)] 17 Claims
 
1. A pharmaceutical formulation comprising:
omecamtiv mecarbil dihydrochloride salt or a pharmaceutically acceptable hydrate thereof;
a control release agent comprising hydroxypropylmethylcellulose;
a pH modifying agent comprising fumaric acid;
a filler; and
a lubricant.